Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment

• Tipo: Artigo em Revista Científica Internacional
• Data: 2016

Autores

Joana A. Loureiro (Autor) FEUP; Bárbara Gomes (Autor) Outra; Gert Fricker (Autor) Outra; Manuel A. N. Coelho (Autor) FEUP; Sandra Rocha (Autor) Outra; Maria do Carmo Pereira (Autor) FEUP

Revista

Título: Colloids and Surfaces B: Biointerfaces

Vol. 145

Páginas: 8-13

ISSN: 0927-7765

Editora: Elsevier

Indexação

ISI Web of Knowledge - 45 Citações

Scopus - 85 Citações

INSPEC

Projetos Associados

LEPAE/CEFT - RL2 - (Bio) Chemical Engineering: Multi-Scale Approaches for Sustainable Environment and Health

LEPABE - Laboratório de Engenharia de Processos, Ambiente, Biotecnologia e Energia

Outras Informações

ID Authenticus: P-00K-E2W

DOI: 10.1016/j.colsurfb.2016.04.041

Abstract (EN): During the last few decades, relevant efforts have been reported to design nanocarriers for drug transport through the blood brain barrier (BBB). New drugs, such as peptide iA beta(5), capable to inhibit the aggregates associated with Alzheimeris disease (AD) are being tested but the most frequent drawback is to reach the brain in the desired concentrations due to the low BBB permeability-surface area. Our approach, as a proof of concept to improve drug transport through the BBB, is based on poly(lactic-co-glycolic acid) (PLGA) nanoparticles with surface functionalized with anti-transferrin receptor monoclonal antibody (OX26) and anti-A beta (DE2B4) to deliver encapsulated iA beta(5) into the brain. Porcine brain capillary endothelial cells (PBCECs) were used as a BBB model to evaluate the system efficacy and toxicity. The uptake of immune nanoparticles with a controlled delivery of the peptide iA beta(5) was substantially increased compared to the nanoparticles (NPs) without monoclonal antibody functionalization.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 6